Literature DB >> 9528825

Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.

E R Sherwood1, J L Van Dongen, C G Wood, S Liao, J M Kozlowski, C Lee.   

Abstract

These studies were undertaken to assess the relative expression and autocrine activation of the epidermal growth factor receptor (EGFR) in normal and transformed prostatic epithelial cells and to determine whether EGFR activation plays a functional role in androgen-stimulated growth of prostate cancer cells in vitro. EGFR expression was determined by Western blot analysis and ELISA immunoassays. Immunoprecipitation of radiophosphorylated EGFR and evaluation of tyrosine phosphorylation was used to assess EGFR activation. The human androgen-independent prostate cancer cell lines PC3 and DU145 exhibited higher levels of EGFR expression and autocrine phosphorylation than normal human prostatic epithelial cells or the human androgen-responsive prostate cancer cell line LNCaP. PC3 and DU145 cells also showed higher levels of autonomous growth under serum-free defined conditions. Normal prostatic epithelial cells expressed EGFR but did not exhibit detectable levels of EGFR phosphorylation when cultured in the absence of exogenous EGF. Addition of EGF stimulated EGFR phosphorylation and induced proliferation of normal cells. LNCaP cells exhibited autocrine phosphorylation of EGFR but did not undergo significant proliferation when cultured in the absence of exogenous growth factors. A biphasic growth curve was observed when LNCaP cells were cultured with dihydrotestosterone (DHT). Maximum proliferation occurred at 1 nM DHT with regression of the growth response at DHT concentrations greater than 1 nM. However, neither EGFR expression nor phosphorylation was altered in LNCaP cells after androgen stimulation. In addition, DHT-stimulated growth of LNCaP cells was not inhibited by anti-EGFR. These studies show that autocrine activation of EGFR is a common feature of prostatic carcinoma cells in contrast to normal epithelial cells. However, EGFR activation does not appear to play a functional role in androgen-stimulated growth of LNCaP cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9528825      PMCID: PMC2150082          DOI: 10.1038/bjc.1998.142

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue.

Authors:  E Glynne-Jones; L Goddard; M E Harper
Journal:  Hum Pathol       Date:  1996-07       Impact factor: 3.466

2.  EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells.

Authors:  T Turner; P Chen; L J Goodly; A Wells
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

3.  Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate.

Authors:  P Davies; C L Eaton
Journal:  Prostate       Date:  1989       Impact factor: 4.104

Review 4.  Endocrine therapy of advanced carcinoma of the prostate.

Authors:  F Daneshgari; E D Crawford
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

5.  Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.

Authors:  S J Leevers; H F Paterson; C J Marshall
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

6.  Two-dimensional protein profiles of cultured stromal and epithelial cells from hyperplastic human prostate.

Authors:  E R Sherwood; L A Berg; R N McEwan; R M Pasciak; J M Kozlowski; C Lee
Journal:  J Cell Biochem       Date:  1989-06       Impact factor: 4.429

7.  Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines.

Authors:  G L Morris; J G Dodd
Journal:  J Urol       Date:  1990-06       Impact factor: 7.450

8.  Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia.

Authors:  S J Maygarden; S Strom; J L Ware
Journal:  Arch Pathol Lab Med       Date:  1992-03       Impact factor: 5.534

Review 9.  Advantages of total androgen blockade in the treatment of advanced prostate cancer.

Authors:  J Geller; J Albert; A Vik
Journal:  Semin Oncol       Date:  1988-04       Impact factor: 4.929

10.  Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines.

Authors:  A MacDonald; F K Habib
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

View more
  36 in total

Review 1.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 2.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Transcriptional Regulation of EGR1 by EGF and the ERK Signaling Pathway in Prostate Cancer Cells.

Authors:  Jennifer Gregg; Gail Fraizer
Journal:  Genes Cancer       Date:  2011-09

4.  Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals.

Authors:  Hikaru Nishimori; Shogo Ehata; Hiroshi I Suzuki; Yoko Katsuno; Kohei Miyazono
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

5.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

Review 6.  Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin Gleave; Hideaki Miyake
Journal:  World J Urol       Date:  2005-01-26       Impact factor: 4.226

7.  Epidermal growth factor increases LRF/Pokemon expression in human prostate cancer cells.

Authors:  Himanshu Aggarwal; Anshu Aggarwal; Devendra K Agrawal
Journal:  Exp Mol Pathol       Date:  2011-05-27       Impact factor: 3.362

8.  Role of proprotein convertases in prostate cancer progression.

Authors:  Frédéric Couture; François D'Anjou; Roxane Desjardins; François Boudreau; Robert Day
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

9.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

Review 10.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.